OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously

Revolutionary technology will further boost OneSource’s scientific services offerings

Roche closes acquisition of LumiraDx’s Point of Care technology

The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances

AbbVie completes acquisition of Cerevel Therapeutics

Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia

Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr

Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore

Zydus receives approval from COFEPRIS to market? Mamitra to treat various cancers

The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2

GSK and Flagship partner to discover novel medicines and vaccines

GSK and Flagship to jointly fund up to $150 million upfront

India reiterates commitment to adolescents on launch of ‘Economic Case for Investment in the Well-being of Adolescents in India’ report

Report highlights significant improvements in adolescent well-being in India

Merck Life Science inks MoU with ICAR-CIFT, Kochi for research in fishing process

USAID and Takeda launch dengue prevention campaign

Campaign launched to spread awareness regarding dengue prevention and control

European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)